The disclosure provides pharmaceutical formulations of the compound of Formula I:

##STR00001##

or a pharmaceutically acceptable salt thereof.

Provided herein are methods for treating acute myeloid leukemia (AML) in a patient with cytopenia when on a combination therapy of venetoclax and azacitidine. Also provided herein are methods of managing a cytopenia in such patient.

Provided herein are methods for treating acute myeloid leukemia (AML) in a patient with cytopenia when on a combination therapy of venetoclax and azacitidine. Also provided herein are methods of managing a cytopenia in such patient.

The present invention describes cannabinoid formulations that combine cannabinoids, such as CBD, with other active agents within the NAD+ precursor class of compounds which, in combination, provide synergistic anti-inflammatory effects. These preparations are capable of increasing anti-inflammatory effects when compared to each individual compound, and are further capable of delivery through a variety of administration routes.

The present invention describes cannabinoid formulations that combine cannabinoids, such as CBD, with other active agents within the NAD+ precursor class of compounds which, in combination, provide synergistic anti-inflammatory effects. These preparations are capable of increasing anti-inflammatory effects when compared to each individual compound, and are further capable of delivery through a variety of administration routes.

Provided are compounds, compositions, and methods for treatment of fungal infections. The compositions comprise the mannose disaccharide analog (2R,3S,4S,5S,6R)-2-((((3S,4R,5R)-4,5-dihydroxypiperidin-3-yl)methyl)thio)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol. Methods are also provided for the treatment of fungal infections comprising contacting the infected site with a therapeutically effective concentration of the present compound or compositions.

Provided are compounds, compositions, and methods for treatment of fungal infections. The compositions comprise the mannose disaccharide analog (2R,3S,4S,5S,6R)-2-((((3S,4R,5R)-4,5-dihydroxypiperidin-3-yl)methyl)thio)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol. Methods are also provided for the treatment of fungal infections comprising contacting the infected site with a therapeutically effective concentration of the present compound or compositions.

Compositions, methods, and kits useful for treating obesity conditions are provided herein. Such compositions can contain synergizing amounts of nicotinamide riboside and/or nicotinamide mononucleotide and/or nicotinic acid metabolites in combination with a flavonoid and/or one or more flavonoid derivatives, with or without resveratrol.

Compositions, methods, and kits useful for treating obesity conditions are provided herein. Such compositions can contain synergizing amounts of nicotinamide riboside and/or nicotinamide mononucleotide and/or nicotinic acid metabolites in combination with a flavonoid and/or one or more flavonoid derivatives, with or without resveratrol.

Compositions, methods, and kits useful for treating obesity conditions are provided herein. Such compositions can contain synergizing amounts of nicotinamide riboside and/or nicotinamide mononucleotide and/or nicotinic acid metabolites in combination with a flavonoid and/or one or more flavonoid derivatives, with or without resveratrol.